Transcriptional responses define dysregulated immune activation in Hepatitis C (HCV)-naïve recipients of HCV-infected donor kidneys

Renal transplantation from hepatitis C (HCV) nucleic acid amplification test-positive (NAAT-positive) donors to uninfected recipients has greatly increased the organ donation pool. However, there is concern for adverse outcomes in these recipients due to dysregulated immunologic activation secondary to active inflammation from acute viremia at the time of transplantation. This includes increased rates of cytomegalovirus (CMV) DNAemia and allograft rejection. In this study, we evaluate transcriptional responses in circulating leukocytes to define the character, timing, and resolution of this immune dysregulation and assess for biomarkers of adverse outcomes in transplant patients. We enrolled 67 renal transplant recipients (30 controls, 37 HCV recipients) and performed RNA sequencing on serial samples from one, 3-, and 6-months post-transplant. CMV DNAemia and allograft rejection outcomes were measured. Least absolute shrinkage and selection operator was utilized to develop gene expression classifiers predictive of clinical outcomes. Acute HCV incited a marked transcriptomic response in circulating leukocytes of renal transplant recipients in the acute post-transplant setting, despite the presence of immunosuppression, with 109 genes significantly differentially expressed compared to controls. These HCV infection-associated genes were reflective of antiviral immune pathways and generally resolved by the 3-month timepoint after sustained viral response (SVR) for HCV. Differential gene expression was also noted from patients who developed CMV DNAemia or allograft rejection compared to those who did not, although transcriptomic classifiers could not accurately predict these outcomes, likely due to sample size and variable time-to-event. Acute HCV infection incites evidence of immune activation and canonical antiviral responses in the human host even in the presence of systemic immunosuppression. After treatment of HCV with antiviral therapy and subsequent aviremia, this immune activation resolves. Changes in gene expression patterns in circulating leukocytes are associated with some clinical outcomes, although larger studies are needed to develop accurate predictive classifiers of these events.

[1]  D. Gjertson,et al.  Acute and Chronic Changes in Gene Expression After CMV DNAemia in Kidney Transplant Recipients , 2021, Frontiers in Immunology.

[2]  Xiaochen Bo,et al.  clusterProfiler 4.0: A universal enrichment tool for interpreting omics data , 2021, Innovation.

[3]  D. Chaussabel,et al.  Transcriptomic Profiling Identifies Neutrophil-Specific Upregulation of Cystatin F as a Marker of Acute Inflammation in Humans , 2021, Frontiers in Immunology.

[4]  A. Ungureanu,et al.  Host immune response in chronic hepatitis C infection: involvement of cytokines and inflammasomes , 2020, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[5]  A. Limaye,et al.  Respiratory viral infection in lung transplantation induces exosomes that trigger chronic rejection , 2020, The Journal of Heart and Lung Transplantation.

[6]  M. Molnar,et al.  Transplantation of kidneys from hepatitis C–infected donors to hepatitis C–negative recipients: Single center experience , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  M. Chattergoon,et al.  Lessons from the real world: HCV‐infected donor kidney transplantation as standard practice , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  Zeguo Sun,et al.  A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection. , 2019, Journal of the American Society of Nephrology : JASN.

[9]  A. Kao,et al.  Insights into Gene Expression Profile Scores and Rejection in Simultaneous Heart‐Kidney Transplant Patients , 2019, Clinical transplantation.

[10]  P. Camp,et al.  Heart and Lung Transplants from HCV‐Infected Donors to Uninfected Recipients , 2019, The New England journal of medicine.

[11]  Graham M Lord,et al.  Development of a multivariable gene-expression signature targeting T-cell-mediated rejection in peripheral blood of kidney transplant recipients validated in cross-sectional and longitudinal samples , 2019, EBioMedicine.

[12]  G. Lauer,et al.  Dynamic changes in innate immune responses during direct‐acting antiviral therapy for HCV infection , 2019, Journal of viral hepatitis.

[13]  C. Rice,et al.  Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance , 2018, PLoS pathogens.

[14]  R. Hasz,et al.  Twelve-Month Outcomes After Transplant of Hepatitis CInfected Kidneys Into Uninfected Recipients , 2018, Annals of Internal Medicine.

[15]  Sangsoo Kim,et al.  Gene expression profiles for predicting antibody‑mediated kidney allograft rejection: Analysis of GEO datasets. , 2018, International journal of molecular medicine.

[16]  J. Felius,et al.  Gene expression profiling scores in dual organ transplant patients are similar to those in heart-only recipients. , 2018, Transplant immunology.

[17]  J. Jang,et al.  Interferon-free treatment for hepatitis C virus infection induces normalization of extrahepatic type I interferon signaling , 2018, Clinical and molecular hepatology.

[18]  T. Asselah,et al.  Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection , 2018, The New England journal of medicine.

[19]  M. Manns,et al.  Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. , 2016, The Journal of infectious diseases.

[20]  T. Berg,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. , 2015, The New England journal of medicine.

[21]  R. Schooley,et al.  Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection , 2015, Hepatology.

[22]  Young-Joon Kim,et al.  Oligoadenylate synthase-like (OASL) proteins: dual functions and associations with diseases , 2015, Experimental & Molecular Medicine.

[23]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[24]  Stefan Zeuzem,et al.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[25]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[26]  K. Volcik,et al.  Differentially regulated gene expression associated with hepatitis C virus clearance. , 2013, The Journal of general virology.

[27]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[28]  Davis J. McCarthy,et al.  Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation , 2012, Nucleic acids research.

[29]  James Yee,et al.  Gene-expression profiling for rejection surveillance after cardiac transplantation. , 2010, The New England journal of medicine.

[30]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[31]  L. Carin,et al.  Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. , 2009, Cell host & microbe.

[32]  Martin M. Schumacher,et al.  Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[33]  D. Greiner,et al.  Viral Infection: A Potent Barrier to Transplantation Tolerance , 2008, Clinical & developmental immunology.

[34]  M. Katze,et al.  Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. , 2006, Gastroenterology.

[35]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  L. Wodicka,et al.  Genomic analysis of the host response to hepatitis C virus infection , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  H. Rollag,et al.  The Impact of Cytomegalovirus Infection and Disease on Rejection Episodes in Renal Allograft Recipients , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[38]  J. Parkin,et al.  An overview of the immune system , 2001, The Lancet.